Literature DB >> 21550121

Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation.

Carey C Dozier1, Ryan M Tarantola, Kim Jiramongkolchai, Sean P Donahue.   

Abstract

PURPOSE: Hematogenous dissemination of fungus of the eyes can manifest as chorioretinitis or endophthalmitis. Early reports of this condition describe the prevalence to range from 10% to 40%; however, more recent studies have suggested a declining prevalence, presumably because of widespread use of prophylactic antifungal therapy and earlier diagnosis and treatment of systemic illness before ocular symptoms become apparent. This study estimates the current prevalence and microbial profile of fungal chorioretinitis and endophthalmitis among patients with positive fungal cultures at a tertiary care medical center.
DESIGN: Retrospective case series. PARTICIPANTS: A total of 211 adult and pediatric inpatients with fungemia.
METHODS: All inpatient consultations at our institution to evaluate for ocular involvement by fungal organisms from June 3, 2006, to September 3, 2009, were reviewed. MAIN OUTCOME MEASURES: The presence or absence of ocular lesions consistent with disseminated fungus.
RESULTS: A total of 211 patients (83 pediatric, 128 adult) had consult requests indicating concern for ocular fungal infection. More than 97% of these patients had at least 1 positive fungal culture. In decreasing order of frequency, the organisms identified were Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and others. More than 98% of all patients were receiving systemic antifungal therapy (average duration 6.5 days) at the time of examination. No pediatric patients and only 2 adult patients had positive findings (i.e., chorioretinitis or endophthalmitis); 1 of these 2 patients was able to verbalize symptoms and reported floaters and blurring, whereas the other patient was unable to verbalize. Visual symptoms were rare (3.5%) among patients with negative findings who could verbalize visual symptoms. Three adults had nonspecific fundus lesions that were considered inconsistent with chorioretinitis.
CONCLUSIONS: Disseminated ocular fungal infection is rare in the current era of widespread prophylactic antifungal therapy. Less than 1% of patients in our study had ocular involvement from fungus, and no patients who were asymptomatic had involvement. We suggest that routine ophthalmic consultation on fungemic inpatients is not an efficient use of clinical resources; however, validation of these findings via a prospective study is desired. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550121     DOI: 10.1016/j.ophtha.2011.01.038

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

1.  Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis.

Authors:  Ying-Lien Chen; Shang-Jie Yu; Hsin-Yu Huang; Ya-Lin Chang; Virginia N Lehman; Fitz Gerald S Silao; Ursela G Bigol; Alice Alma C Bungay; Anna Averette; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2014-01-17

Review 2.  Diagnostic dilemmas in retinitis and endophthalmitis.

Authors:  J L Davis
Journal:  Eye (Lond)       Date:  2011-11-25       Impact factor: 3.775

3.  Trends in Infantile Endogenous Endophthalmitis Hospitalizations in the United States: An Analysis from 2007 through 2014 Using the National Inpatient Sample.

Authors:  Chandana Papudesu; Tahreem Mir; Wei Fang; Jesse Thompson; David M Hinkle
Journal:  Ophthalmol Retina       Date:  2020-05-06

4.  Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting.

Authors:  Devon H Ghodasra; Kian Eftekhari; Ankoor R Shah; Brian L VanderBeek
Journal:  Ophthalmology       Date:  2014-08-10       Impact factor: 12.079

5.  Fundoscopy screening for intraocular candida in patients with positive blood cultures-is it justified?

Authors:  Mariam El-Abiary; Brian Jones; Graeme Williams; David Lockington
Journal:  Eye (Lond)       Date:  2018-07-06       Impact factor: 3.775

6.  Ocular manifestations of candidemia in children.

Authors:  Julie L Fierro; Priya A Prasad; Brian T Fisher; Jeffrey S Gerber; Susan E Coffin; Thomas J Walsh; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

7.  Duration of treatment for candidemia and risk for late-onset ocular candidiasis.

Authors:  O Blennow; L Tallstedt; B Hedquist; B Gårdlund
Journal:  Infection       Date:  2012-12-02       Impact factor: 3.553

8.  Endophthalmitis: A review of recent trends.

Authors:  Janice R Safneck
Journal:  Saudi J Ophthalmol       Date:  2012-03-03

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Authors:  J L Livermore; T W Felton; J Abbott; A Sharp; J Goodwin; L Gregson; P A Warn; S J Howard; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.